International Stem Cell Corp. is a clinical stage biotechnology company, which engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market, and Therapeutic Market. The Cosmetic Market segment develops, manufactures, and markets a cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment involves in the development, manufacture, and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases, and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich, and Gregory S. Keller on August 17, 2001 and is headquartered in Carlsbad, CA.